Quoin Pharmaceuticals (QNRX) Competitors

Quoin Pharmaceuticals logo
$3.56 +0.20 (+5.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.63 +0.07 (+1.94%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QNRX vs. MNOV, HRTX, CING, VRCA, and FBIO

Should you buy Quoin Pharmaceuticals stock or one of its competitors? Quoin Pharmaceuticals's main competitors and comparable companies include MediciNova (MNOV), Heron Therapeutics (HRTX), Cingulate (CING), Verrica Pharmaceuticals (VRCA), and Fortress Biotech (FBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Quoin Pharmaceuticals compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

MediciNova currently has a consensus price target of $7.75, indicating a potential upside of 478.36%. Quoin Pharmaceuticals has a consensus price target of $17.33, indicating a potential upside of 415.87%. Given MediciNova's stronger consensus rating and higher probable upside, equities analysts clearly believe MediciNova is more favorable than Quoin Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediciNova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, MediciNova had 6 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 9 mentions for MediciNova and 3 mentions for Quoin Pharmaceuticals. MediciNova's average media sentiment score of 1.20 beat Quoin Pharmaceuticals' score of 0.37 indicating that MediciNova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediciNova
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quoin Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Quoin Pharmaceuticals has a net margin of 0.00% compared to MediciNova's net margin of -1,126.60%. MediciNova's return on equity of -26.47% beat Quoin Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MediciNova-1,126.60% -26.47% -24.24%
Quoin Pharmaceuticals N/A -227.75%-149.97%

MediciNova has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

MediciNova has higher revenue and earnings than Quoin Pharmaceuticals. MediciNova is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNova$410K167.43-$12M-$0.21N/A
Quoin PharmaceuticalsN/AN/A-$15.81M-$19.44N/A

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 7.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

MediciNova beats Quoin Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Heron Therapeutics?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Quoin Pharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -14.55%. Quoin Pharmaceuticals' return on equity of -227.75% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Quoin PharmaceuticalsN/A -227.75% -149.97%
Heron Therapeutics -14.55%-277.36%-8.76%

Quoin Pharmaceuticals presently has a consensus price target of $17.33, indicating a potential upside of 415.87%. Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 608.72%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Quoin Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Quoin Pharmaceuticals has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quoin PharmaceuticalsN/AN/A-$15.81M-$19.44N/A
Heron Therapeutics$154.90M0.35-$20.19M-$0.12N/A

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 7.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Heron Therapeutics had 5 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 8 mentions for Heron Therapeutics and 3 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.37 beat Heron Therapeutics' score of -0.06 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quoin Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Heron Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Quoin Pharmaceuticals beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Cingulate?

Cingulate (NASDAQ:CING) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Cingulate is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/A-$22.45M-$2.77N/A
Quoin PharmaceuticalsN/AN/A-$15.81M-$19.44N/A

Cingulate has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Cingulate's return on equity of -177.94% beat Quoin Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CingulateN/A -177.94% -108.95%
Quoin Pharmaceuticals N/A -227.75%-149.97%

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 7.5% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cingulate had 1 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 4 mentions for Cingulate and 3 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.37 beat Cingulate's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cingulate
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quoin Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cingulate currently has a consensus price target of $27.00, suggesting a potential upside of 472.03%. Quoin Pharmaceuticals has a consensus price target of $17.33, suggesting a potential upside of 415.87%. Given Cingulate's higher probable upside, analysts plainly believe Cingulate is more favorable than Quoin Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cingulate
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Cingulate and Quoin Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Verrica Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 3 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.37 beat Verrica Pharmaceuticals' score of -0.12 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quoin Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Verrica Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Quoin Pharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Quoin Pharmaceuticals currently has a consensus target price of $17.33, suggesting a potential upside of 415.87%. Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 303.40%. Given Quoin Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Quoin Pharmaceuticals is more favorable than Verrica Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Verrica Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Quoin Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -189.23%. Quoin Pharmaceuticals' return on equity of -227.75% beat Verrica Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Quoin PharmaceuticalsN/A -227.75% -149.97%
Verrica Pharmaceuticals -189.23%-423.63%-102.46%

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 7.5% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quoin PharmaceuticalsN/AN/A-$15.81M-$19.44N/A
Verrica Pharmaceuticals$35.58M1.52-$17.89M-$2.22N/A

Summary

Quoin Pharmaceuticals beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Fortress Biotech?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Quoin Pharmaceuticals has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quoin PharmaceuticalsN/AN/A-$15.81M-$19.44N/A
Fortress Biotech$63.26M0.97$6.82M$2.300.79

Fortress Biotech has a net margin of 143.04% compared to Quoin Pharmaceuticals' net margin of 0.00%. Fortress Biotech's return on equity of 61.84% beat Quoin Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Quoin PharmaceuticalsN/A -227.75% -149.97%
Fortress Biotech 143.04%61.84%35.15%

Quoin Pharmaceuticals currently has a consensus target price of $17.33, suggesting a potential upside of 415.87%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 834.07%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Quoin Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Fortress Biotech had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 6 mentions for Fortress Biotech and 3 mentions for Quoin Pharmaceuticals. Fortress Biotech's average media sentiment score of 0.60 beat Quoin Pharmaceuticals' score of 0.37 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quoin Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 7.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Quoin Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QNRX vs. The Competition

MetricQuoin PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$17.09M$13.38B$7.59B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E Ratio-0.1828.1833.6629.92
Price / SalesN/A7.028.325.64
Price / CashN/A15.6321.0121.90
Price / Book0.605.394.443.72
Net Income-$15.81M$2.88B$3.50B$393.72M
7 Day Performance-5.32%-5.22%-6.53%-6.06%
1 Month Performance-8.72%-4.78%-4.92%-7.39%
1 Year Performance-81.50%-7.33%-1.72%-7.50%

Quoin Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QNRX
Quoin Pharmaceuticals
3.9917 of 5 stars
$3.56
+6.0%
$17.33
+386.9%
-79.3%$17.09MN/AN/A4
MNOV
MediciNova
2.9491 of 5 stars
$1.41
+0.7%
$7.75
+449.6%
-5.0%$69.40M$410KN/A6
HRTX
Heron Therapeutics
1.7504 of 5 stars
$0.36
-4.0%
$2.00
+456.6%
-74.1%$68.21M$154.90MN/A128
CING
Cingulate
1.7927 of 5 stars
$4.68
+2.6%
$27.00
+476.9%
+41.7%$68.05MN/AN/A14
VRCA
Verrica Pharmaceuticals
2.8774 of 5 stars
$3.91
+11.1%
$12.67
+224.0%
-15.8%$67.17M$30.32MN/A76

Related Companies and Tools


This page (NASDAQ:QNRX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners